Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
Puma Biotechnology (NASDAQ: PBYI) has announced its participation in the upcoming TD Cowen 45th Annual Health Care Conference. The company's CEO Alan H. Auerbach will deliver a corporate presentation on March 5, 2025, at 11:10 a.m. ET at the Boston Marriott Copley Place.
The conference is scheduled to run from March 3-5, 2025. Investors and interested parties can access a live webcast of the presentation through Puma Biotechnology's website. The presentation recording will remain available for replay on the company's website for 30 days following the event.
Puma Biotechnology (NASDAQ: PBYI) ha annunciato la sua partecipazione alla prossima 45ª Conferenza Annuale sulla Salute di TD Cowen. Il CEO dell'azienda, Alan H. Auerbach, terrà una presentazione aziendale il 5 marzo 2025, alle 11:10 ET presso il Boston Marriott Copley Place.
La conferenza è prevista dal 3 al 5 marzo 2025. Gli investitori e le parti interessate possono accedere a un webcast in diretta della presentazione tramite il sito web di Puma Biotechnology. La registrazione della presentazione sarà disponibile per la visione on-demand sul sito dell'azienda per 30 giorni dopo l'evento.
Puma Biotechnology (NASDAQ: PBYI) ha anunciado su participación en la próxima 45ª Conferencia Anual de Salud de TD Cowen. El CEO de la compañía, Alan H. Auerbach, ofrecerá una presentación corporativa el 5 de marzo de 2025, a las 11:10 a.m. ET en el Boston Marriott Copley Place.
La conferencia está programada del 3 al 5 de marzo de 2025. Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través del sitio web de Puma Biotechnology. La grabación de la presentación estará disponible para su reproducción en el sitio de la empresa durante 30 días después del evento.
푸마 생명공학 (NASDAQ: PBYI)는 다가오는 TD Cowen 제45회 연례 건강 관리 회의에 참여할 것이라고 발표했습니다. 회사의 CEO인 앨런 H. 아우어바흐는 2025년 3월 5일 오전 11시 10분 ET에 보스턴 메리어트 코플리 플레이스에서 기업 발표를 진행할 예정입니다.
회의는 2025년 3월 3일부터 5일까지 진행됩니다. 투자자 및 관심 있는 분들은 푸마 생명공학 웹사이트를 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 발표 녹화는 행사 후 30일 동안 회사 웹사이트에서 재생할 수 있습니다.
Puma Biotechnology (NASDAQ: PBYI) a annoncé sa participation à la prochaine 45e Conférence Annuelle sur la Santé de TD Cowen. Le PDG de la société, Alan H. Auerbach, fera une présentation d'entreprise le 5 mars 2025 à 11h10 ET au Boston Marriott Copley Place.
La conférence est prévue du 3 au 5 mars 2025. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via le site web de Puma Biotechnology. L'enregistrement de la présentation sera disponible en replay sur le site de l'entreprise pendant 30 jours après l'événement.
Puma Biotechnology (NASDAQ: PBYI) hat seine Teilnahme an der bevorstehenden 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Der CEO des Unternehmens, Alan H. Auerbach, wird am 5. März 2025 um 11:10 Uhr ET im Boston Marriott Copley Place eine Unternehmenspräsentation halten.
Die Konferenz findet vom 3. bis 5. März 2025 statt. Investoren und Interessierte können über die Website von Puma Biotechnology auf ein Live-Webcast der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird 30 Tage nach der Veranstaltung auf der Unternehmenswebsite für eine Wiederholung verfügbar sein.
- None.
- None.
A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226129242/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Olipriya Das, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
olipriya.das@russopartnersllc.com
Source: Puma Biotechnology, Inc.
FAQ
When is Puma Biotechnology (PBYI) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Puma Biotechnology's (PBYI) TD Cowen conference presentation?
Where is the TD Cowen Healthcare Conference 2025 being held for PBYI's presentation?
Who will be presenting for Puma Biotechnology (PBYI) at the TD Cowen conference?
